Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Bill Wexler's Profits of DOOM -- Ignore unavailable to you. Want to Upgrade?

To: Hank who wrote (642)	4/9/1998 7:13:00 PM
From: Biojunkie	Read Replies (2) \| Respond to of 4634

Hank, Aids Research and Human Retrovirus Volume 9,November 8, 1993 "Here we report that DHEA and a synthetic analog to DHEA,8354, can also reduce HIV-1 latency reactivation in the ACH-2 cell line. The inhibitory effect is not due to cytotoxicity of these drugs." This article goes on to say that DHEA and this anolog are non-competitive inhibitors to G6PDH and NADPH (Cellular energy factors). If DHEA or anologs were truly toxic to cells why would Nurocrine Sciences be using it for Alzheimers and Gene labs for Lupas?